

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: left; padding: 2px;">Complete if Known</th> </tr> <tr> <td style="width: 30%; padding: 2px;">Application Number</td> <td style="padding: 2px;">09/754,775</td> </tr> <tr> <td style="padding: 2px;">Filing Date</td> <td style="padding: 2px;">January 4, 2001</td> </tr> <tr> <td style="padding: 2px;">First Named Inventor</td> <td style="padding: 2px;">David J. Grainger</td> </tr> <tr> <td style="padding: 2px;">Group Art Unit</td> <td style="padding: 2px;">1628</td> </tr> <tr> <td style="padding: 2px;">Examiner Name</td> <td style="padding: 2px;">Jennifer Kim</td> </tr> </table>	Complete if Known		Application Number	09/754,775	Filing Date	January 4, 2001	First Named Inventor	David J. Grainger	Group Art Unit	1628	Examiner Name	Jennifer Kim
Complete if Known													
Application Number	09/754,775												
Filing Date	January 4, 2001												
First Named Inventor	David J. Grainger												
Group Art Unit	1628												
Examiner Name	Jennifer Kim												
Sheet 1 of 3	Attorney Docket No: 295.009US3												

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
--------------------	---------------------	------------------	---	----------------------------

FOREIGN PATENT DOCUMENTS

Examiner Initial *	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T 1
--------------------	---------------------	------------------	---	-----

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS

Examiner Initial *	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 1
	"Abstract for TOX-42 - 1,3-Diphenylguanidine (CASRN 102-06-7)", NTP Study Reports, (09/1995), 2	
	"Application Serial No. 10/729,056, Response filed 02-23-10 to Non Final Office Action mailed 10-23-09", 18 pgs	
	"Application Serial No.10/729,056, Final Office Action mailed 06-15-10", 34 pgs	
	"Canadian Application Serial No. 2,223,595, Office Action dated 01-17-07", 2 pgs.	
	"Canadian Application Serial No. 2,223,595, Response filed 06-13-07 to Office Action dated 01-17-07", 6 pgs.	
	"European Application Serial No. 07021554.6, Communication dated 06-18-08", 2 pgs.	
	"European Application Serial No. 07021554.6, Response filed 07-09-08 to Communication dated 06-18-08", 23 pgs.	
	"Japanese Application Serial No. 9-502239, Decision of Final Rejection mailed 04-07-09", (w/ English Translation), 23 pgs.	
	"Japanese Application Serial No.2006-322111, Office Action Mailed 12/22/2009", (w/ English Translation), 8 pgs.	
	AGNUSDEI, D., et al., "Results of International Clinical Trials with Raloxifene", Ann Endocrino (Paris) PubMed, Abstract 60(3), (9/1999), 1	
	BLUM, A., et al., "Selective estrogen receptor modulator effects on serum lipoproteins and vascular function in postmenopausal women and in hypercholesterolemic men.", Ann N Y Acad Sci., 949, (Dec., 2001), 168-74	
	BUTTA, A., et al., "Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment", Cancer Res., 52(15), (Aug. 1, 1992), 4261-4	
	CASTRO, MR, et al., "Clomiphene-induced Severe Hypertriglyceridemia and Pancreatitis", Mayo Clin. Proc., (11/1999), 1125-1128	
	ERKKOLA, R., et al., "Bone Mineral Density and lipid Changes during 5 years of follow-up in a study of prevention of breast cancer with toremifene in healthy, high-risk pre- and post-menopausal women.", Breast Cancer Res Treat, 93(3), Department of Obstetrics and	

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	<i>Complete if Known</i>	
	Application Number	09/754,775
	Filing Date	January 4, 2001
	First Named Inventor	David J. Grainger
	Group Art Unit	1628
	Examiner Name	Jennifer Kim
Sheet 2 of 3	Attorney Docket No: 295.009US3	

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS

Examiner Initial *	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 1
	Gynaecology, (Oct 2005), 277-87	
	FRANK, R. N., "On the pathogenesis of diabetic retinopathy", Ophthalmology, 98(5), (May, 1991), 586-93	
	GENNARI, L., "Lasofofene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis.", Drugs Today (Barc.), 42(6), (Jun., 2006), 355-67	
	HARVEY, H. A., et al., "Toremifene: an evaluation of its safety profile", Breast, 15(2), (Nov 9, 2005), 142-57	
	JORDAN, V. C., "Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents.", J Med Chem., 46(7), (Mar. 27, 2003), 1081-111	
	KELLEN, J. A., "Raloxifene", Curr Drug Targets, 2(4), (Dec., 2001), 423-5	
	KOCKAYA, EA, et al., "Pathological and Biochemical Effects of Therapeutic and Supratherapeutic Doses of Celecoxib in Wistar Albino Male Rats", Drug Chem Toxicol, 2010 June 16 (Epub ahead of print) Abstract, (06/2010), 1	
	KULLO, IFTIKHAR J., et al., "Conditional Risk Factors for Atherosclerosis", Mayo Clinic Proc.; 80(2), (02/2005), 219-230	
	KUSAMA, M., et al., "Crossover trial for lipid abnormality in postmenopausal breast cancer patients during selective estrogen receptor modulators (SERMs) administrators", Breast Cancer Res Treat, 88(1), (Nov 2004), 9-16	
	KUSAMA, M., et al., "Effects of Toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer", Breast Cancer Res Treat, 88(1), (Nov 2004), 1-8	
	MULDER, H., et al., "The Effects of Idoxifene on Markers of Cardiovascular Risk in Osteopenic Postmenopausal Women", Cardiovascular Diseases in Women, Vol. 19, Univ. of Minn Bio-Medical Library. ISSN 0195 668X, Abstract Supplemental, (08/1998), 3	
	MULDER, H., et al., "The effects of idoxifene on markers of cardiovascular risk in osteopenic postmenopausal women", European Heart Journal, 19(Suppl), (Aug., 1998), 237	
	OKUBO, MICHIOHITO, et al., "Effects of Probucol on Hypercholesterolemia in Renal Transplant Patients", Kidney International, 56,S229-S230, (1999), 4	
	SATO, Y., "TGF- β and vascular disorders. Focusing on angiogenesis and atherosclerosis", Jikken Kagaku, 10(15), (1992), 1908-1912	
	SMITH, MATTHEW R., et al., "Toremifene Improves Lipid Profiles in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer: Interim Analysis of a Multicenter Phase III Study", Journal of Clinical Oncology, Vol. 26, No. 11, (04-10-2008), 1824-1829	
	TARAS, T. L, et al., "Clinical pharmacokinetics of toremifene", Clin Pharmacokinet., 39(5), (Nov., 2000), 327-34	
	VOGELVANG, T. E, et al., "Hormone replacement therapy, selective estrogen receptor modulators, and tissue-specific compounds: cardiovascular effects and clinical implications.", Treat Endocrinol., 3(2), (2004), 105-15	

EXAMINER

DATE CONSIDERED

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: left; padding: 2px;"><i>Complete if Known</i></th> </tr> <tr> <td style="width: 35%; padding: 2px;">Application Number</td> <td style="padding: 2px;">09/754,775</td> </tr> <tr> <td style="padding: 2px;">Filing Date</td> <td style="padding: 2px;">January 4, 2001</td> </tr> <tr> <td style="padding: 2px;">First Named Inventor</td> <td style="padding: 2px;">David J. Grainger</td> </tr> <tr> <td style="padding: 2px;">Group Art Unit</td> <td style="padding: 2px;">1628</td> </tr> <tr> <td style="padding: 2px;">Examiner Name</td> <td style="padding: 2px;">Jennifer Kim</td> </tr> </table>	<i>Complete if Known</i>		Application Number	09/754,775	Filing Date	January 4, 2001	First Named Inventor	David J. Grainger	Group Art Unit	1628	Examiner Name	Jennifer Kim
<i>Complete if Known</i>													
Application Number	09/754,775												
Filing Date	January 4, 2001												
First Named Inventor	David J. Grainger												
Group Art Unit	1628												
Examiner Name	Jennifer Kim												
Sheet 3 of 3	Attorney Docket No: 295.009US3												

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS		
Examiner Initial *	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 1
	WISEMAN, H., et al., "Tamoxifen inhibits lipid peroxidation in cardiac microsomes. Comparison with liver microsomes and potential relevance to the cardiovascular benefits associated with cancer prevention and treatment by tamoxifen.", Biochem Pharmacol., 45(9), (May 5, 1993), 1851-5	

EXAMINER

DATE CONSIDERED